Hologic, Inc. $HOLX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 12.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 319,848 shares of the medical equipment provider’s stock after purchasing an additional 35,667 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Hologic were worth $21,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Hologic by 10.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after buying an additional 3,520 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after acquiring an additional 3,790 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Hologic by 71.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 10,909 shares of the medical equipment provider’s stock valued at $707,000 after purchasing an additional 4,548 shares during the period. Farther Finance Advisors LLC increased its position in Hologic by 38.3% during the second quarter. Farther Finance Advisors LLC now owns 2,538 shares of the medical equipment provider’s stock worth $165,000 after purchasing an additional 703 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Hologic by 129.4% during the second quarter. GAMMA Investing LLC now owns 7,269 shares of the medical equipment provider’s stock worth $474,000 after purchasing an additional 4,100 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on HOLX shares. Evercore ISI cut shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $79.31.

Hologic Price Performance

HOLX opened at $75.11 on Friday. The stock’s 50-day moving average price is $74.78 and its 200 day moving average price is $70.45. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.34. The firm has a market cap of $16.74 billion, a price-to-earnings ratio of 30.29, a PEG ratio of 2.13 and a beta of 0.69. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the prior year, the firm earned $1.01 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.